VIDAVIDA Global Inc.

🇺🇸 US
2.48
USD
Analysis Scores
Lothien Robustness Score?
-
Neden bu skor?
Damodaran ?
-
Dalio Risk ?
-
Piotroski ?
N/A
Yetersiz çeyrek verisi: 4 mevcut, en az 5 gerekli
Graham ?
Negatif HBK
Company is loss-making (EPS = -0.2245 TL) — Graham formula requires positive earnings
Lothien Robustness Summary
26/100
Lothien Sağlamlık: Çok Zayıf (26/100)
Temel göstergelerin çoğu olumsuz. Lothien sağlamlık skoru düşük seviyede. | Kısa Vade: Olumsuz | Uzun Vade: Nötr | Pozitif: 4 | Negatif: 6 | Nötr: 0
Net Zarar
Son çeyrekte -$2M zarar açıklandı. Yatırımcı dikkatli olmalı.
Çeyreklik Kâr Düşüşü
Net kâr bir önceki çeyreğe göre %-41.0 geriledi (-$1M → -$2M). Kısa vadede olumsuz sinyal.
Yıllık Kâr Geriledi
Geçen yılın aynı dönemine göre net kâr %-2107.6 düştü. Uzun vadede endişe verici.
Yıllık Hasılat Büyümesi Güçlü
Yıllık hasılat %+344.0 arttı. Şirket büyüyor.
Brüt Marj Daraldı
Brüt kâr marjı %52.1 → %48.6 (-3.5 puan). Maliyet baskısı veya rekabet artıyor.
Güçlü Likidite
Cari oran 18.31x — kısa vadeli borçları rahat karşılıyor.
FAVÖK Düşüşü
FAVÖK çeyreklik %-95.5 düştü. Operasyonel performans zayıflıyor.
Negatif ROE
ROE: %-24.1. Şirket özsermayesini eritiyor.
Özkaynak Büyümesi
Özkaynak çeyreklik %+255.0 arttı. Şirket içsel birikimle güçleniyor.
Sonraki Çeyrek: Artış Beklentisi
Pusla tahminine göre bir sonraki çeyrekte kâr %+16.8 artabilir (-$2M → -$1M).

Data date date not measured Not investment advice; the figures are rule-based model output. How the scores are computed

Score record
Data date date not measured
Update frequency Scheduled analysis run on business days at 19:30 Istanbul time; not every symbol is refreshed in every run

Method summaryThe Lothien Robustness Score (0-100) is a weighted combination of sub-scores computed by fixed rules from published financial statements and price data (Damodaran valuation, Dalio risk, Piotroski F-score, earnings quality, momentum and others). The rules are applied automatically to every covered stock, with weights that vary by sector.

AssumptionsCalculations rest on the company's latest published financial statements and on price data that may be delayed. Where four quarters have not been published, annual figures may be scaled from the available quarters. Model parameters such as the risk-free rate, the risk premium and long-term growth are fixed assumptions per exchange and contain no company-specific expectation.

Conflict of interestNo statement has been published on whether MIDAK, the operator of Lothien, or its team hold positions in these stocks. The figures are produced automatically by the same rules, without regard to any such position.

WarningThis information is not within the scope of investment advisory services and is not investment advice. The figures are the output of rule-based models and may not suit your financial situation or your risk and return preferences. Making an investment decision on the basis of this information alone may not lead to results that meet your expectations.

Model output; not investment advice; different models can disagree. Report an error

Valuation
Potential?
-
Balance Sheet Analysis? Q2026/9
Son 4 çeyrek ardışık zarar
Fiyat TRAMA-99 hafif altında: %+0.0
Direnç seviyesi: TRAMA-99 = 2.48 USD
Fundamental & Technical Analysis
Profitability
Net Profit Margin %-484.2
Net profit margin %-484.2 — loss period. Compared to previous quarter -120.8 point decrease.
ROE - Return on Equity (TTM) %-24.1
ROE %-24.1 — negative return on equity.
EBITDA Margin %-424.1
EBITDA margin %-424.1 — operational loss.
Gross Profit Margin %48.6
Gross profit per revenue %48.6. Strong pricing power.
Free Cash Flow Margin (TTM) %-336.0
TTM Free Cash Flow is %-336.0'i. Negative FCF — company consuming cash.
Valuation
P/B Ratio 2.09x Sector: 3.59x
PD/DD 2.09x — sector median's (3.59x) well below. Cheap relative to book value.
Indebtedness
Current Ratio 18.31x
Current ratio 18.31x — current assets are 2x short-term liabilities. Very healthy liquidity.
Debt / Equity 0.01x
Low leverage — majority of assets financed by equity.
Interest Coverage -1002.3x
Interest coverage -1002.3x — critical level. Risk of difficulty in interest payments.
Growth
Revenue Growth (YoY) %+344.0
Revenue YoY %344.0 grew (2026/6) — strong growth. Sector expansion and/or market share increase.
Net Profit Growth (YoY) %-2107.6
Loss %2107.6 increased — losses deepening.
Score Explanations
Lothien Robustness
-
Good robustness (57/100). The company shows a generally balanced financial profile; some areas have room for improvement.
Potential
-
Plus %28.2 expected value (3.18) vs current price comparison. 1/4 valuation models could be calculated. Model confidence %48.
Components: P/B target: 3.94
Damodaran Valuation
-
Low Damodaran score (20/100). ROIC (%-83.0) below cost of capital. DCF analysis does not support current price.
Very Weak
Dalio Risk Analysis
-
Low debt risk (83/100). Interest coverage ratio -1002.3x — weak, fragile.
Leverage: 100/100 | Debt Service: 100/100 | Quality: 17/100
ROIC - Return on Capital
%-83.0
ROIC (%-83.0) cost of capital (15.8%) below → destroying value.
WACC: %15.8
Debt Cycle Phase
Early Expansion
Debt decreasing, growth gaining momentum. Company in balance sheet cleanup phase.
Piotroski F-Score
—
Graham Intrinsic Value
—
Company is loss-making (EPS = -0.2245 TL) — Graham formula requires positive earnings
⚖️ Sector Comparison
P/B Ratio
2.09x vs 3.59x
Compared to sector %42 cheaper (by book value)
ROIC vs WACC
%-83.0 vs %15.8 WACC
ROIC 98.8 bps below cost of capital
↔
TRAMA-99 Trend — Near TRAMA
Price (2.48), TRAMA-99 line (2.48) at close levels (%+0.0). Important decision zone — breakout direction will determine the trend.
Price:: 2.48
TRAMA: 2.48
Difference: %+0.0
Charts
Indicators
BB deviation ?
RSI thresholds ?

Price Chart ?
▲ içeriden alım · ▼ içeriden satım · ★ katalizör (haber-sezgisel) · ■ 13D aktivist · ■ 13G pasif — SEC Form 4 ~2 gün gecikmeli, yalnız yönetici/direktör/%10+ sahip; katalizör = haber-sezgisel; 13D/G = %5+ pay bildirimi ~5 iş günü gecikmeli.
RSI (14) ?
Bollinger Bands ?
MACD ?
Kurumsal Holdings — 13F (çeyreklik) ?

İçeriden Alım-Satım Akışı

Kim aldı, kim sattı, ne kadar

VIDA — Participation Finance Compliance
Loading…
The Lothien health scores and analyses on this page are for informational purposes only. They do not constitute investment advice. Please consult a licensed investment advisor before making investment decisions.